Metformin, as the first-line oral drug for
type 2 diabetes, has proven benefits against aging,
cancer and
cardiovascular diseases. But the influence of
metformin to the immune response and its molecular mechanisms remain obscure.
Metformin increases resistance to not only the Gram-negative pathogens Pseudomonas aeruginosa and Salmonella enterica but also the Gram-positive pathogens Enterococcus faecalis and Staphylococcus aureus. Meanwhile,
metformin protects the animals from the
infection by enhancing the tolerance to the pathogen
infection rather than by reducing the bacterial burden. Through the screening of classical immune pathways in C. elegans, we find
metformin enhances innate immunity through
p38 MAPK pathway. Furthermore, activated p38/PMK-1 by
metformin acts on the intestine for innate immune response. In addition,
metformin-treated mice have increased resistance to P. aeruginosa PA14
infection and significantly increased the levels of active PMK-1. Therefore, promoted p38/PMK-1-mediated innate immunity by
metformin is conserved from worms to mammals. Our work provides a conserved mechanism by which
metformin enhances immune response and boosts its therapeutic application in the treatment of pathogen
infection.